Literature DB >> 10733511

Variant genotypes of FcgammaRIIIA influence the development of Kaposi's sarcoma in HIV-infected men.

T L Lehrnbecher1, C B Foster, S Zhu, D Venzon, S M Steinberg, K Wyvill, J A Metcalf, S S Cohen, J Kovacs, R Yarchoan, A Blauvelt, S J Chanock.   

Abstract

Disturbances in inflammatory cytokine production and immune regulation coupled with human herpesvirus-8 (HHV-8) infection underlie the current understanding of the pathogenesis of Kaposi's sarcoma (KS), the most common HIV-associated malignancy. The low affinity Fc gamma receptors (FcgammaR) for IgG link humoral and cellular immunity by mediating interaction between antibodies and effector cells, such as phagocytes and natural killer cells. We examined the frequency of polymorphic forms of the low affinity FcgammaRs, FcgammaRIIA, FcgammaRIIIA, and FcgammaRIIIB in 2 cohorts of HIV-infected men with KS and found that the FcgammaRIIIA genotype exerts a significant influence on susceptibility to or protection from KS. The FF genotype was underrepresented in patients with KS, whereas the VF genotype was associated with development of KS. A similar association was observed between FcgammaRIIIA genotypes and HHV-8 seropositivity. These observations suggest a possible role for FcgammaRIIIA in the development of KS during HIV infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733511

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Kaposi's sarcoma and its associated herpesvirus.

Authors:  Enrique A Mesri; Ethel Cesarman; Chris Boshoff
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

2.  Short communication: Fc gamma receptors IIa and IIIa genetic polymorphisms do not predict HIV-1 disease progression in Kenyan women.

Authors:  Julie F Weis; R Scott McClelland; Walter Jaoko; Kishor N Mandaliya; Julie Overbaugh; Susan M Graham
Journal:  AIDS Res Hum Retroviruses       Date:  2014-11-13       Impact factor: 2.205

Review 3.  The role of Fc receptors in HIV infection and vaccine efficacy.

Authors:  Sarah L Cocklin; Joern E Schmitz
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283

4.  EPHA2 sequence variants are associated with susceptibility to Kaposi's sarcoma-associated herpesvirus infection and Kaposi's sarcoma prevalence in HIV-infected patients.

Authors:  Melissa J Blumenthal; Charlotte Schutz; Graeme Meintjes; Zainab Mohamed; Marc Mendelson; Jon M Ambler; Denise Whitby; Romel D Mackelprang; Sinead Carse; Arieh A Katz; Georgia Schäfer
Journal:  Cancer Epidemiol       Date:  2018-08-31       Impact factor: 2.984

5.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

6.  Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination.

Authors:  Donald N Forthal; Erin E Gabriel; Angela Wang; Gary Landucci; Tran B Phan
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

7.  A candidate gene approach for virally induced cancer with application to HIV-related Kaposi's sarcoma.

Authors:  Brahim Aissani; Howard W Wiener; Kui Zhang; Richard A Kaslow; Kisani M Ogwaro; Sadeep Shrestha; Lisa P Jacobson
Journal:  Int J Cancer       Date:  2013-07-27       Impact factor: 7.396

8.  High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression.

Authors:  Bhawna Poonia; Gustavo H Kijak; C David Pauza
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

9.  A role for host activation-induced cytidine deaminase in innate immune defense against KSHV.

Authors:  Elena Bekerman; Diana Jeon; Michele Ardolino; Laurent Coscoy
Journal:  PLoS Pathog       Date:  2013-11-07       Impact factor: 6.823

10.  SNP screening of central MHC-identified HLA-DMB as a candidate susceptibility gene for HIV-related Kaposi's sarcoma.

Authors:  B Aissani; A K Boehme; H W Wiener; S Shrestha; L P Jacobson; R A Kaslow
Journal:  Genes Immun       Date:  2014-07-10       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.